Featured Publications
Access to COVID-19 Vaccines in High-, Middle-, and Low-Income Countries Hosting Clinical Trials
Ramachandran R, Ross JS, Miller JE. Access to COVID-19 Vaccines in High-, Middle-, and Low-Income Countries Hosting Clinical Trials. JAMA Network Open 2021, 4: e2134233. PMID: 34792596, PMCID: PMC8603077, DOI: 10.1001/jamanetworkopen.2021.34233.Peer-Reviewed Original ResearchMeSH KeywordsClinical Trials as TopicCOVID-19COVID-19 VaccinesCross-Sectional StudiesDeveloped CountriesDeveloping CountriesHealth Services AccessibilityHumansIncomePovertyEvaluation of Drug Trials in High-, Middle-, and Low-Income Countries and Local Commercial Availability of Newly Approved Drugs
Miller JE, Mello MM, Wallach JD, Gudbranson EM, Bohlig B, Ross JS, Gross CP, Bach PB. Evaluation of Drug Trials in High-, Middle-, and Low-Income Countries and Local Commercial Availability of Newly Approved Drugs. JAMA Network Open 2021, 4: e217075. PMID: 33950209, PMCID: PMC8100865, DOI: 10.1001/jamanetworkopen.2021.7075.Peer-Reviewed Original ResearchMeSH KeywordsAfricaClinical Trials as TopicCross-Sectional StudiesDeveloped CountriesDeveloping CountriesDrug ApprovalDrug CostsHumansMarketingPharmaceutical PreparationsUnited StatesConceptsFDA approvalHigh-income countriesDrug approvalIncome countriesNovel drugsDrug Administration (FDA) drug approvalsRegulatory agency websitesCross-sectional analysisProportion of drugPrimary outcomeFDA drug approvalsProportion of countriesDrug trialsMAIN OUTCOMEUS FoodClinical researchCountry income levelLow-income countriesMarketing approvalTrialsGoogle ScholarDrugsDrug companiesApprovalMedian
2023
Transparency of Results Reporting in Cancer Clinical Trials
Kao J, Ross J, Miller J. Transparency of Results Reporting in Cancer Clinical Trials. JAMA Network Open 2023, 6: e2328117. PMID: 37556143, PMCID: PMC10413165, DOI: 10.1001/jamanetworkopen.2023.28117.Peer-Reviewed Original ResearchClinical Trial Diversity—Will We Know It When We See It?
Varma T, Gross C, Miller J. Clinical Trial Diversity—Will We Know It When We See It? JAMA Oncology 2023, 9: 765-767. PMID: 37022678, DOI: 10.1001/jamaoncol.2023.0143.Peer-Reviewed Original Research
2019
Sharing of clinical trial data and results reporting practices among large pharmaceutical companies: cross sectional descriptive study and pilot of a tool to improve company practices
Miller J, Ross JS, Wilenzick M, Mello MM. Sharing of clinical trial data and results reporting practices among large pharmaceutical companies: cross sectional descriptive study and pilot of a tool to improve company practices. The BMJ 2019, 366: l4217. PMID: 31292127, PMCID: PMC6614834, DOI: 10.1136/bmj.l4217.Peer-Reviewed Original ResearchMeSH KeywordsClinical Trials as TopicCross-Sectional StudiesDrug ApprovalDrug IndustryHumansInformation DisseminationPilot ProjectsStakeholder ParticipationTime FactorsConceptsClinical trial dataTrial dataDrug approvalSectional descriptive studyPharmaceutical companiesFDA drug approvalsLarge pharmaceutical companiesClinical trialsDrug levelsNew drug approvalsUS FoodDrug AdministrationNew drug applicationsFDA approvalPatientsNovel drugsDescriptive studyDrug applicationTrialsDrugsExternal investigatorsSharing scoreDrug companiesTrial transparencyStudy measures
2018
Registration, results reporting, and publication bias of clinical trials supporting FDA approval of neuropsychiatric drugs before and after FDAAA: a retrospective cohort study
Zou CX, Becker JE, Phillips AT, Garritano JM, Krumholz HM, Miller JE, Ross JS. Registration, results reporting, and publication bias of clinical trials supporting FDA approval of neuropsychiatric drugs before and after FDAAA: a retrospective cohort study. Trials 2018, 19: 581. PMID: 30352601, PMCID: PMC6199729, DOI: 10.1186/s13063-018-2957-0.Peer-Reviewed Original ResearchConceptsRetrospective cohort studyPublication biasNeuropsychiatric indicationsCohort studyClinical trialsRelative riskEfficacy trialsFDA approvalPositive trialsFisher's exact testRecent FDA approvalDrug Administration Amendments ActClinical trial publicationsTRIAL REGISTRATIONMAIN OUTCOMEProportion of trialsNeuropsychiatric drugsNew drug approvalsTrial publicationsExact testMedical interventionsTrialsDrug approvalNew drugsDrugsDelays in the Publication of Important Clinical Trial Findings in Oncology
Qunaj L, Jain RH, Atoria CL, Gennarelli RL, Miller JE, Bach PB. Delays in the Publication of Important Clinical Trial Findings in Oncology. JAMA Oncology 2018, 4: e180264-e180264. PMID: 29710325, PMCID: PMC6145729, DOI: 10.1001/jamaoncol.2018.0264.Peer-Reviewed Original ResearchPostmarket studies required by the US Food and Drug Administration for new drugs and biologics approved between 2009 and 2012: cross sectional analysis
Wallach JD, Egilman AC, Dhruva SS, McCarthy ME, Miller JE, Woloshin S, Schwartz LM, Ross JS. Postmarket studies required by the US Food and Drug Administration for new drugs and biologics approved between 2009 and 2012: cross sectional analysis. The BMJ 2018, 361: k2031. PMID: 29794072, PMCID: PMC5967364, DOI: 10.1136/bmj.k2031.Peer-Reviewed Original ResearchConceptsProspective cohort studyCohort studyClinical trialsPostmarketing requirementsTimeliness of registrationNew drugsUS FoodDrug AdministrationFDA approvalStudy designNumber of patientsSectional analysisPostmarket studiesFirst approvalRegistrySecondary analysisTrialsBiologicsDrugsComparator typeAdministrationApprovalFDAFDA's authority
2017
Measuring clinical trial transparency: an empirical analysis of newly approved drugs and large pharmaceutical companies
Miller JE, Wilenzick M, Ritcey N, Ross JS, Mello MM. Measuring clinical trial transparency: an empirical analysis of newly approved drugs and large pharmaceutical companies. BMJ Open 2017, 7: e017917. PMID: 29208616, PMCID: PMC5728266, DOI: 10.1136/bmjopen-2017-017917.Peer-Reviewed Original ResearchCharacterizing expanded access and compassionate use programs for experimental drugs
Miller JE, Ross JS, Moch KI, Caplan AL. Characterizing expanded access and compassionate use programs for experimental drugs. BMC Research Notes 2017, 10: 350. PMID: 28754150, PMCID: PMC5534121, DOI: 10.1186/s13104-017-2687-5.Peer-Reviewed Original ResearchMeSH KeywordsClinical Trials as TopicCompassionate Use TrialsDrugs, InvestigationalHumansProgram DevelopmentAssociation of the FDA Amendment Act with trial registration, publication, and outcome reporting
Phillips AT, Desai NR, Krumholz HM, Zou CX, Miller JE, Ross JS. Association of the FDA Amendment Act with trial registration, publication, and outcome reporting. Trials 2017, 18: 333. PMID: 28720112, PMCID: PMC5516301, DOI: 10.1186/s13063-017-2068-3.Peer-Reviewed Original ResearchConceptsCardiovascular diseaseTRIAL REGISTRATIONFDA approvalNew drugsClinical trial registrationFDA Amendments ActDrug Administration Amendments ActAccessible trial registryClinical trial publicationsTrials RegistryResultsBetween 2005Efficacy trialsFDA reviewersTrial publicationsOutcome reportingMedical literatureReviewer interpretationsTrialsReporting of findingsDiseaseFDA documentsDrugsDiabetesFDAAAReviewers
2016
Incorporating ethical principles into clinical research protocols: a tool for protocol writers and ethics committees
Li RH, Wacholtz MC, Barnes M, Boggs L, Callery-D'Amico S, Davis A, Digilova A, Forster D, Heffernan K, Luthin M, Lynch HF, McNair L, Miller JE, Murphy J, Van Campen L, Wilenzick M, Wolf D, Woolston C, Aldinger C, Bierer BE. Incorporating ethical principles into clinical research protocols: a tool for protocol writers and ethics committees. Journal Of Medical Ethics 2016, 42: 229. PMID: 26811365, PMCID: PMC4819642, DOI: 10.1136/medethics-2014-102540.Peer-Reviewed Original ResearchConceptsResearch ethics committee reviewResearch ethics issuesCritical ethical issuesEthics committee reviewEthical principlesEthics issuesEthics reviewEthics sectionEthical issuesClinical research protocolsEthics CommitteeProtocol writersCommittee reviewProtocol approvalResearch protocolReview processTool kitIssuesMultinational settingClinical Trial CenterDeliberationHarvardClinical trial protocolSpecific attentionWriters
2015
Clinical trial registration, reporting, publication and FDAAA compliance: a cross-sectional analysis and ranking of new drugs approved by the FDA in 2012
Miller JE, Korn D, Ross JS. Clinical trial registration, reporting, publication and FDAAA compliance: a cross-sectional analysis and ranking of new drugs approved by the FDA in 2012. BMJ Open 2015, 5: e009758. PMID: 26563214, PMCID: PMC4654354, DOI: 10.1136/bmjopen-2015-009758.Peer-Reviewed Original ResearchGatekeepers for pragmatic clinical trials
Whicher DM, Miller JE, Dunham KM, Joffe S. Gatekeepers for pragmatic clinical trials. Clinical Trials 2015, 12: 442-448. PMID: 26374683, PMCID: PMC4592478, DOI: 10.1177/1740774515597699.Peer-Reviewed Original ResearchMeSH KeywordsBiomedical ResearchClinical Trials as TopicDecision MakingHumansResearch DesignUnited StatesThe ethics and regulatory landscape of including vulnerable populations in pragmatic clinical trials
Welch MJ, Lally R, Miller JE, Pittman S, Brodsky L, Caplan AL, Uhlenbrauck G, Louzao DM, Fischer JH, Wilfond B. The ethics and regulatory landscape of including vulnerable populations in pragmatic clinical trials. Clinical Trials 2015, 12: 503-510. PMID: 26374681, PMCID: PMC4662375, DOI: 10.1177/1740774515597701.Peer-Reviewed Original ResearchConceptsPragmatic clinical trialsClinical trialsPregnant womenVulnerable populationsClinical trial settingsMental disabilitiesPhysical handicapTraditional clinical trialsDisadvantaged personsVulnerable subjectsTrial settingsHealth interventionsClinical settingClinical researchTrialsNeonatesFetusesWomenSubjectsDisabilityChildrenVulnerable research subjectsPopulationSpecific recommendationsPersons
2013
How a Clinical Trial Registry Became a Symbol of Misinformation
Miller JE. How a Clinical Trial Registry Became a Symbol of Misinformation. The Hastings Center Report 2013, 43: 11-12. PMID: 24249467, DOI: 10.1002/hast.226.Peer-Reviewed Original ResearchMeSH KeywordsBiasClinical Trials as TopicDrug IndustryHumansPoliticsRegistriesResearch DesignScientific MisconductSEER ProgramUnited StatesConceptsFirst national registryClinical Trials RegistryOngoing clinical trialsNational Cancer InstitutePublic health goalsNational Cancer ActTrials RegistryOpen trialNational registryClinical trialsCancer InstituteRegistryHealth goalsCancer ActCancer therapyPatientsTrialsPharmaceutical companiesDread diseaseDoctorsTherapyCancerDisease